Please use this identifier to cite or link to this item:
|Title:||213-Bismuth-labeled antibody to gp41 glycoprotein kills ART-treated lymphocytes from HIV patients and HIV-infected monocytes in human blood brain barrier model|
|Authors:||MCFARREN A; TSUKROV D; EUGENIN E; LOPEZ L; WILLIAMS D; MORGENSTERN Alfred; BRUCHERTSEIFER Frank; ZOLLA-PAZNER S.; GORNY M.k.; Casadevall Arturo; BERMAN J; DADACHOVA E.|
|Citation:||Proceedings of the 8th Symposium on Targeted Alpha Therapy p. 29|
|Publisher:||Oak Ridge National Laboratory|
|Type:||Articles in periodicals and books|
|Abstract:||Eliminating virally infected cells is an essential component of HIV eradication strategy. In addition, many patients on antiretroviral therapy (ART) suffer from HIV-associated neurocognitive disorders because the brain becomes a reservoir for infection. There is a need for drugs that can enter into the CNS and eradicate the infection. Radioimmunotherapy (RIT), a clinically established method to kill cells using radiolabeled antibodies, was recently applied to target the HIV gp41 glycoprotein expressed on the surface of infected cells.|
|JRC Directorate:||Nuclear Safety and Security|
Files in This Item:
There are no files associated with this item.
Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.